Board Appointment

RNS Number:4552Z
Axis-Shield PLC
08 March 2006

                                AXIS-SHIELD PLC

                               BOARD APPOINTMENT


Dundee, Scotland, 8 March 2006 - Axis-Shield plc (LSE: ASD, OSE: ASD), the
international in vitro diagnostics company, today announces the appointment of
Staffan Ek as a non-executive director. Staffan has extensive knowledge of the
healthcare sector, acquired over thirty years in the industry, primarily with
Pharmacia, Boehringer Mannheim and Roche Diagnostics. He recently retired from
Roche, where he was Head of Diabetes Care, an Executive Director of Roche
Diagnostics, and a permanent participant of the Corporate Executive Committee of
F Hoffmann-La Roche AG, Basle, Switzerland.

Nigel Keen, Chairman of Axis-Shield, commented:

"We welcome Staffan to the Board. His wide experience within the healthcare
sector at senior executive level will be an invaluable asset to Axis-Shield,
particularly as the Company continues its expansion into primary care
diagnostics via its AFINION(TM) platform."

With reference to paragraphs 9.6.13 (1) - (6) of the FSA's Listing Rules, there
are no disclosures required.


Enquiries:


Axis-Shield plc
Svein Lien, CEO                           Tel:  [phone]
Paul Garvey, Finance Director             Tel:  [phone]

Financial Dynamics
David Yates / Sarah Macleod               Tel:  [phone]


Notes to Editors

Axis-Shield is an international in vitro diagnostics company, headquartered in
Dundee with R&D and manufacturing bases in Dundee and Oslo.  The Group
specialises in the development, manufacture and marketing of innovative
proprietary diagnostics kits in areas of clinical need, including cardiovascular
and neurological diseases, rheumatoid arthritis, alcohol abuse and diabetes. It
has a special focus on effective testing at the point of care, for improved
patient management.

News releases and company information are available at www.axis-shield.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAAKOKQOBKDFNK